اخبار و اعلانات

 آمار

تعداد نشریات286
تعداد نشریات سازمان84
تعداد شماره‌ها3,000
تعداد مقالات33,581
تعداد مشاهده مقاله44,329,930
تعداد دریافت فایل اصل مقاله24,438,823
Pal, Ashish, Sundararajan, Raja. (1403). Characterization of forced degradants of Tegafur, Gimeracil, and Oteracil potassium by Liquid Chromatographic-Electrospray Ionization-Mass Spectrometry and simultaneous estimation of triple combination in drug substance and finished pharmaceutical Dosage Form. سامانه مدیریت نشریات علمی, 79(2), 287-302. doi: 10.32592/ARI.2024.79.2.287
Ashish Kumar Pal; Raja Sundararajan. "Characterization of forced degradants of Tegafur, Gimeracil, and Oteracil potassium by Liquid Chromatographic-Electrospray Ionization-Mass Spectrometry and simultaneous estimation of triple combination in drug substance and finished pharmaceutical Dosage Form". سامانه مدیریت نشریات علمی, 79, 2, 1403, 287-302. doi: 10.32592/ARI.2024.79.2.287
Pal, Ashish, Sundararajan, Raja. (1403). 'Characterization of forced degradants of Tegafur, Gimeracil, and Oteracil potassium by Liquid Chromatographic-Electrospray Ionization-Mass Spectrometry and simultaneous estimation of triple combination in drug substance and finished pharmaceutical Dosage Form', سامانه مدیریت نشریات علمی, 79(2), pp. 287-302. doi: 10.32592/ARI.2024.79.2.287
Pal, Ashish, Sundararajan, Raja. Characterization of forced degradants of Tegafur, Gimeracil, and Oteracil potassium by Liquid Chromatographic-Electrospray Ionization-Mass Spectrometry and simultaneous estimation of triple combination in drug substance and finished pharmaceutical Dosage Form. سامانه مدیریت نشریات علمی, 1403; 79(2): 287-302. doi: 10.32592/ARI.2024.79.2.287

Characterization of forced degradants of Tegafur, Gimeracil, and Oteracil potassium by Liquid Chromatographic-Electrospray Ionization-Mass Spectrometry and simultaneous estimation of triple combination in drug substance and finished pharmaceutical Dosage Form

Archives of Razi Institute
مقاله 8، دوره 79، شماره 2، خرداد و تیر 2024، صفحه 287-302    اصل مقاله (986.42 K)
نوع مقاله: Original Articles
شناسه دیجیتال (DOI): 10.32592/ARI.2024.79.2.287
نویسندگان
Ashish Kumar Pal* ؛ Raja Sundararajan
Department of Pharmaceutical Analysis, GITAM Institute of Pharmacy, GITAM (Deemed to be University), Gandhi Nagar, Rushikonda, Visakhapatnam, Pin code: 530 045, Andhra Pradesh (State), India.
چکیده
Tegafur, gimeracil, and oteracil potassium are widely used pharmaceuticals to treat lung cancers

of the gastrointestinal tract like the oral cavity, esophagus, colon and rectum, pancreas, and also

non-small cell lung cancers. Literature review revealed that no study has yet offered a completely

stability-demonstrating, validated liquid chromatography-mass spectrometric approach for the

concurrent estimation of tegafur, gimeracil, and oteracil potassium along with all known

degradation products. The simultaneous detection of tegafur, gimeracil, and oteracil potassium,

and their forced degradation products characterization, necessitated the invention of a simple,

faster, and less expensive method. The goal of the study was to follow ICH method validation

standards to develop and validate a fast, easy, and rugged liquid chromatography-mass

spectrometry (LC-MS) technique for the concurrent estimation of Tegafur, gimeracil, and oteracil

potassium in drug substance and finished dosage form according to ICH method validation

guidelines. Tegafur, gimeracil, and oteracil potassium were examined on Waters HPLC Alliance

system coupled to SCIEX QTRAP 5500 mass spectrometer endowed with an interface capable of

carryout electrospray ionization. The tegafur, gimeracil, and oteracil peaks eluted at retention times

of 2.338 min., 3.756 min., and 5.338 min. respectively. The limit of detection (LOD) values of

tegafur, gimeracil, and oteracil were detected to be 0.6, 0.174, and 0.474 μg/mL, respectively

however the results for quantification limit (LOQ) were calculated to be 2.0, 0.58, 1.58 µg/mL

concentration, respectively. Tegafur, gimeracil, and oteracil had linear ranges of 50-300 µg/ml,

14.5-87 µg/ml, and 39.5-237 µg/ml, respectively, with regression coefficients of 0.99956, 0.99986,

and 0.999479. Accuracy values for tegafur, gimeracil, and oteracil in the ranges of 50%, 100%

and 150% for each were respectively, were determined to be 99.9%, 99.9%, and 99.4%. The %

RSD for six replicates was less than 2% for precision. According to ICH Q2 guidelines, this

approach was effectively evaluated with LC-MS to validate the chemical structures of freshly

created tegafur, gimeracil, and oteracil degradation products. An accurate and sensitive LC-MS

technique was developed and validated for the concurrent quantification of tegafur, gimeracil, and

oteracil potassium in drug material and medicinal dosage form.
کلیدواژه‌ها
Tegafur؛ Gimeracil؛ Oteracil؛ liquid chromatography mass-spectrometry (LC-MS) technique؛ degradation study
سایر فایل های مرتبط با مقاله
مراجع
  1. Ikenaka K, shirasaka T, kitano S, Fujii S. Effect of uracil on metabolism of 5-fluorouracil in vitro. GANN Jpn J Cancer Res. 1979;70(3):353-9.
  2. Sakata KI, Someya M, Matsumoto Y, Tauchi H, Kai M, Toyota M, Takagi M, Hareyama M, Fukushima M. Gimeracil, an inhibitor of dihydropyrimidine dehydrogenase, inhibits the early step in homologous recombination. Cancer Sci. 2011;102(9):1712-6. DOI: 10.1111/j.1349-7006.2011.02004.x
  3. National Center for Biotechnology Information. PubChem Compound Summary for CID 4604, Oxonic Acid. Retrieved, 2023 from https://pubchem.ncbi.nlm.nih.gov/compound/Oxonic-Acid.
  4. Wen L, You C, Lu X, Zhang L. Phase II trial of concurrent chemoradiotherapy with S‑1 versus weekly cisplatin for locoregionally advanced nasopharyngeal carcinoma. Clin. Oncol. 2015;3(3):687-91. DOI: 10.3892/mco.2015.529
  5. Emi M, Yamaguchi Y, Hihara J, Hironaka K, Okada M. Phase I trial of oxaliplatin plus S-1 chemotherapy in patients with metastatic colorectal cancer. Oncol. Lett. 2010;1(1):95-8. DOI: 10.3892/ol_00000017
  6. MISTRY V, YELWE A, DESHPANDE A. A simultaneous estimation, validation and forced degradation studies of 5-fluorouracil and tegafur in a pharmaceutical dosage form using reversed-phase high-performance liquid chromatography method. Asian J Pharm Clin Res. 2018;11(12):132-7.DOI: DOI: 10.22159/ajpcr.2018.v11i12.27858
  7. Nakamoto M, Ishigouoka H, Sato K, Yamauchi T, Tonogi M, Yamane GY, Tanaka Y, Ichiba H, Fukushima T, Inouye Y. Feasibility of Bioavailability Testing by Simultaneous Determination of Serum Concentrations of Tegafur and 5-fluorouracil after TS-1 Oral or Tube Administration for Chemotherapy in Oral Cancer Patients. J. Health Sci.2010;56(6):684-9.DOI: doi.org/10.1248/jhs.56.684
  8. Kawabata N, Sugiyama S, Kuwamura T, Odaka Y, Satoh T. Simultaneous determination of tegafur and 5‐fluorouracil in serum by GLC using nitrogen‐sensitive detection. J Pharm Sci .1983;72(10):1162-5.DOI: 10.1002/jps.2600721013
  9. Liu HY, Ding L, Yu Y, Chu Y, Zhu H. Comparison of three derivatization reagents for the simultaneous determination of highly hydrophilic pyrimidine antitumor agents in human plasma by LC–MS/MS. J. Chromatogr. B.2012;893:49-56.DOI: 10.1097/FTD.0b013e3182693687
  10. Li W, Lin H, Song N, Chen G, Li X, Zhao H. Equilibrium solubility investigation and thermodynamic aspects of biologically active gimeracil (form P) dissolved in aqueous co-solvent mixtures of isopropanol, N, N-dimethylformamide, ethylene glycol and dimethylsulfoxide. J. Chem. Thermodyn. 2019;133:19-28. DOI: 10.1016/j.jct.2019.01.026
  11. Gu Y, Lu R, Si D, Liu C. Simultaneous determination of tegafur and gimeracil in human plasma by liquid chromatography/tandem mass spectrometry. Anal. Sci. 2009;25(10):1211-5.DOI: 10.2116/analsci.25.1211
  12. Liu HY, Ding L, Yu Y, Chu Y, Zhu H. Comparison of three derivatization reagents for the simultaneous determination of highly hydrophilic pyrimidine antitumor agents in human plasma by LC–MS/MS. J. Chromatogr. B. 2012;893:49-56. DOI: 10.1016/j.jchromb.2012.02.033
  13. Launay M, Nasser Y, Tholance Y, Dellinger S, Gonzalo P, Delavenne X. Delaying centrifugation and freezing by adding a dihydropyrimidine dehydrogenase inhibitor such as gimeracil to blood sample is not a valid option to simplify the preanalytic step for the screening of dihydropyrimidine dehydrogenase deficiency using uracilemia. Ther. Drug Monit. 2020;42(2):344-5. DOI: 10.1097/FTD.0000000000000716
  14. Chen Y, Jiang Y, Qu J, Wang Q, Bai Y, Shi J, Shi Y, Chen X, Yang N, Heng J, Li K. Pharmacokinetic and bioequivalence study of new S-1 capsule in Chinese cancer patients. Eur. J. Pharm. Sci. 2020;151:105384. DOI: 10.1016/j.ejps.2020.105384
  15. Peer CJ, McManus TJ, Hurwitz HI, Petros WP. Development and utilization of a combined LC–UV and LC–MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT®/leucovorin. J. Chromatogr.B.2012;898:32-7.DOI: 10.1016/j.jchromb.2012.04.010
  16. Lee HW, Seong SJ, Kang WY, Ohk B, Gwon MR, Kim BK, Cho S, Cho K, Sung YK, Yoon YR, Kim JG. Pharmacokinetic and bioequivalence study between two formulations of S-1 in Korean gastric cancer patients. Drug Des Devel Ther.2019:3127-36. DOI: 10.2147/DDDT.S219822
  17. Sugiyama E, Kaniwa N, Kim SR, Hasegawa R, Saito Y, Ueno H, Okusaka T, Ikeda M, Morizane C, Kondo S, Yamamoto N. Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms. Clin. Pharmacokinet. 2010;49:549-58. DOI: 10.2165/11532970-000000000-00000
  18. Kochi M, Fujii M, Kanamori N, Kaiga T, Aizaki K, Takahashi T, Takayama T. Effect of gastrectomy on the pharmacokinetics of S-1, an oral fluoropyrimidine, in resectable gastric cancer patients. Cancer Chemother. Pharmacol. 2007;60:693-701.DOI: 10.1007/s00280-007-0415-x
  19. Kim TH, Shin S, Shin JC, Bulitta JB, Weon KY, Yoo SD, Park GY, Jeong SW, Kwon DR, Min BS, Woo MH. Effect of sipjeondaebo-tang on the pharmacokinetics of S-1, an anticancer agent, in rats evaluated by population pharmacokinetic modeling. Molecules. 2017;22(9):1488. DOI: 10.3390/molecules22091488
آمار
تعداد مشاهده مقاله: 11,815
تعداد دریافت فایل اصل مقاله: 403


counter
سامانه مدیریت نشریات علمی. طراحی و پیاده سازی از سیناوب